Drug intelligence / Profile preview

calcium carbonate (Rowa Pharmaceuticals)

Development stage: Unknown
Lead developer: Rowa
Modality: Small Molecules
Administration: Topical

Overview

Rowarolan is a sterile cutaneous powder containing 100% calcium carbonate, developed and manufactured by Rowa Pharmaceuticals. It is indicated for the topical treatment of minor wounds, cuts, abrasions, pressure sores (bedsores), and leg ulcers. The powder functions as a protective and drying agent, absorbing wound exudate and creating a physical barrier that protects the area from external irritation and promotes a dry environment conducive to natural healing. It is a long-established product, particularly in the Irish market, where it is regulated as a medicinal product for wound management.

Brand names: Rowarolan
Other names: calcium carbonate powderRowarolan PowderRowarolan Cutaneous Powder

Beyond the preview

Go deeper on calcium carbonate (Rowa Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on calcium carbonate (Rowa Pharmaceuticals).

Explore the full profile